237 related articles for article (PubMed ID: 29923797)
1. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
2. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
3. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
4. Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
Ji Y; Wang Q; Zhao Q; Zhao S; Li L; Sun G; Ye L
Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9557-9568. PubMed ID: 31686145
[TBL] [Abstract][Full Text] [Related]
5. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
6. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
[TBL] [Abstract][Full Text] [Related]
9. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
10. Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
Zai W; Chen W; Han Y; Wu Z; Fan J; Zhang X; Luan J; Tang S; Jin X; Fu X; Gao H; Ju D; Liu H
Carcinogenesis; 2020 May; 41(3):345-357. PubMed ID: 31175354
[TBL] [Abstract][Full Text] [Related]
11. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
[TBL] [Abstract][Full Text] [Related]
12. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
13. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
14. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
Booth L; Roberts JL; Conley A; Cruickshanks N; Ridder T; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 Mar; 15(3):305-16. PubMed ID: 24351423
[TBL] [Abstract][Full Text] [Related]
16. Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Booth L; Cruickshanks N; Tavallai S; Roberts JL; Peery M; Poklepovic A; Dent P
Cancer Biol Ther; 2014; 15(12):1646-57. PubMed ID: 25482938
[TBL] [Abstract][Full Text] [Related]
17. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
[TBL] [Abstract][Full Text] [Related]
18. Niraparib for the treatment of ovarian cancer.
Essel KG; Moore KN
Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447
[TBL] [Abstract][Full Text] [Related]
19. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
20. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
